Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 192 articles:
HTML format



Single Articles


    July 2022
  1. ZHAO D, Zarif M, Eladl E, Capo-Chichi JM, et al
    NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1.
    Leuk Res. 2022;118:106869.
    PubMed     Abstract available


  2. CHAUVET P, Nibourel O, Berthon C, Goursaud L, et al
    Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
    Leuk Res. 2022;118:106871.
    PubMed     Abstract available


  3. LIU J, Qin W, Wang B, Wang Z, et al
    PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
    Leuk Res. 2022;118:106859.
    PubMed     Abstract available


    June 2022
  4. OTHMAN T, Moskoff BN, Ho G, Tenold ME, et al
    Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
    Leuk Res. 2022;119:106885.
    PubMed     Abstract available


  5. TATARIAN J, Byrd K, Male HJ, Lin TL, et al
    Central nervous system involvement in adult acute myeloid leukemia patients.
    Leuk Res. 2022;118:106882.
    PubMed    


  6. HASHIMOTO H, Gungor D, Krickeberg N, Schmitt J, et al
    TH1 cytokines induce senescence in AML.
    Leuk Res. 2022;117:106842.
    PubMed     Abstract available


    May 2022
  7. KIM K, Bazinet A, Loghavi S, Konopleva M, et al
    Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine.
    Leuk Res. 2022;119:106884.
    PubMed    


  8. GOSWAMI S, Chiang CL, Zapolnik K, Nunes J, et al
    ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
    Leuk Res. 2022;118:106872.
    PubMed    


  9. STEIDL C, Aroldi A, Mologni L, Crespiatico I, et al
    Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience.
    Leuk Res. 2022;118:106861.
    PubMed     Abstract available


  10. TASHAKORI M, Wang W, Kadia TM, Daver NG, et al
    Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
    Leuk Res. 2022;118:106860.
    PubMed     Abstract available


  11. KIM T, Ahn JS, Son MH, Novitzky-Basso I, et al
    Genetic changes during leukemic transformation to secondary acute myeloid leukemia from myeloproliferative neoplasms.
    Leuk Res. 2022;118:106858.
    PubMed     Abstract available


  12. KARBALIVAND M, Almada LL, Ansell SM, Fernandez-Zapico ME, et al
    MLL1 inhibition reduces IgM levels in Waldenstrom macroglobulinemia.
    Leuk Res. 2022;116:106841.
    PubMed     Abstract available


  13. NORVILAS R, Batiuskaite R, Dirse V, Semaskeviciene R, et al
    Population-based targeted RNA sequencing reveals novel disease-related gene fusions in pediatric and adult T-ALL.
    Leuk Res. 2022;116:106825.
    PubMed     Abstract available


    April 2022
  14. ARORA S, Zainaldin C, Bathini S, Gupta U, et al
    Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia.
    Leuk Res. 2022;117:106844.
    PubMed     Abstract available


  15. BAI H, Zhang Q, Zhang S, Wang J, et al
    Multiple cells of origin in common with various types of mouse N-Myc acute leukemia.
    Leuk Res. 2022;117:106843.
    PubMed     Abstract available


    March 2022
  16. NGUYEN PC, Donati V, Vassili C, Grigg AP, et al
    Real-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.
    Leuk Res. 2022 Mar 27:106837. doi: 10.1016/j.leukres.2022.106837.
    PubMed    


  17. SHEHATA AMF, Gohar SF, Muharram NM, Eldin SMK, et al
    LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients.
    Leuk Res. 2022;116:106838.
    PubMed     Abstract available


  18. TRIGUERO A, Xicoy B, Zamora L, Jimenez MJ, et al
    Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
    Leuk Res. 2022;116:106836.
    PubMed     Abstract available


  19. JELLOUL FZ, Yang R, Garces S, Kanagal-Shamanna R, et al
    Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.
    Leuk Res. 2022;116:106827.
    PubMed     Abstract available


  20. BHREATHNACH U, Doherty D, Murphy K, Flynn CM, et al
    Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia.
    Leuk Res. 2022;116:106823.
    PubMed    


  21. KAMATH-LOEB AS, Shen JC, Schmitt MW, Kohrn BF, et al
    Accurate detection of subclonal variants in paired diagnosis-relapse acute myeloid leukemia samples by next generation Duplex Sequencing.
    Leuk Res. 2022;115:106822.
    PubMed     Abstract available


  22. HERNANDEZ-BOLUDA JC, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, et al
    Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.
    Leuk Res. 2022;115:106821.
    PubMed     Abstract available


  23. WANG X, Bajpai AK, Gu Q, Centeno A, et al
    A systems genetics approach delineates the role of Bcl2 in leukemia pathogenesis.
    Leuk Res. 2022;114:106804.
    PubMed     Abstract available


    February 2022
  24. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
    Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
    Leuk Res. 2022 Feb 23:106811. doi: 10.1016/j.leukres.2022.106811.
    PubMed    


  25. ROSTAMI M, Kharajo RS, Parsa-Kondelaji M, Ayatollahi H, et al
    Altered expression of NEAT1 variants and P53, PTEN, and BCL-2 genes in patients with acute myeloid leukemia.
    Leuk Res. 2022;115:106807.
    PubMed     Abstract available


  26. NUHOGLU KANTARCI E, Eskazan AE
    Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.
    Leuk Res. 2022;114:106808.
    PubMed     Abstract available


  27. DE BELLIS E, Imbergamo S, Candoni A, Lico A, et al
    Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
    Leuk Res. 2022;114:106803.
    PubMed     Abstract available


  28. KUSNE Y, Xie Z, Patnaik MM
    Clonal hematopoiesis: Molecular and clinical implications.
    Leuk Res. 2022;113:106787.
    PubMed     Abstract available


  29. CHORNENKI NLJ, Siegal DM, Qamar K, Woolgar S, et al
    Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
    Leuk Res. 2022;113:106788.
    PubMed    


    January 2022
  30. PARK H, Kang S, Kim I, Kim S, et al
    The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.
    Leuk Res. 2022;114:106791.
    PubMed     Abstract available


  31. THOMAS JW, Jamy O, Shah MV, Vachhani P, et al
    Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
    Leuk Res. 2022;112:106770.
    PubMed     Abstract available


  32. SORIGUE M, Arenillas L, Xicoy B, Andrade-Campos M, et al
    Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis.
    Leuk Res. 2022;112:106771.
    PubMed    


  33. ALAYED K, Meyerson HJ
    Decreased CD177(pos) neutrophils in myeloid neoplasms is associated with NPM1, RUNX1, TET2, and U2AF1 S34F mutations.
    Leuk Res. 2022;112:106752.
    PubMed     Abstract available


  34. PARKER C, Ayton D, Zomer E, Liew D, et al
    Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system.
    Leuk Res. 2022;112:106748.
    PubMed     Abstract available


    December 2021
  35. SHERBAN A, Raanani P, Gurion R, Wolach O, et al
    Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
    Leuk Res. 2021;113:106773.
    PubMed     Abstract available


  36. WEBSTER JA, Robinson TM, Blackford AL, Warlick E, et al
    A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML.
    Leuk Res. 2021;111:106737.
    PubMed     Abstract available


  37. GAJZER D, Logothetis CN, Sallman DA, Calon G, et al
    MYC overexpression is associated with an early disease progression from MDS to AML.
    Leuk Res. 2021;111:106733.
    PubMed     Abstract available


  38. OBENG-KUSI M, MacDonald K, van Lierde MA, Lee CS, et al
    No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
    Leuk Res. 2021;111:106734.
    PubMed     Abstract available


  39. KOTA V, Brummendorf TH, Gambacorti-Passerini C, Lipton JH, et al
    Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosomepositive leukemias.
    Leuk Res. 2021;111:106690.
    PubMed     Abstract available


  40. BAYRAK AG, Daglar Aday A, Yavuz AS, Nalcaci M, et al
    Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Leuk Res. 2021;111:106725.
    PubMed     Abstract available


  41. MCBRIDE A, Daniel S, Driessen MT, Szende A, et al
    Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
    Leuk Res. 2021;111:106671.
    PubMed     Abstract available


  42. BORSKY M, Hrabcakova V, Novotna J, Brychtova Y, et al
    Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion.
    Leuk Res. 2021;111:106684.
    PubMed     Abstract available


    November 2021
  43. KAIVERS J, Peters J, Rautenberg C, Schroeder T, et al
    The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.
    Leuk Res. 2021;112:106757.
    PubMed     Abstract available


  44. PERMIKIN Z, Popov A, Verzhbitskaya T, Riger T, et al
    Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t(6;11)(q27;q23)/KMT2A-AFDN: A case report.
    Leuk Res. 2021;112:106758.
    PubMed    


  45. SREEDHARANUNNI S, Jamwal M, Balakrishnan A, Aravindan AV, et al
    Chronic eosinophilic leukemia with recurrent STAT5B N642H mutation-An entity with features of myelodysplastic syndrome/ myeloproliferative neoplasm overlap.
    Leuk Res. 2021;112:106753.
    PubMed    


  46. CIROVIC A, Cirovic A
    Iron deficiency as promoter of heavy metals-induced acute myeloid leukemia.
    Leuk Res. 2021;112:106755.
    PubMed     Abstract available


  47. NORSKOV KH, Fridthjof K, Kampmann P, Dunweber A, et al
    A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia.
    Leuk Res. 2021;112:106756.
    PubMed     Abstract available


  48. KEE KM, Kim SH, Yang SY, Shin JU, et al
    Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
    Leuk Res. 2021;112:106754.
    PubMed     Abstract available


  49. MIRFAKHRAIE R, Noorazar L, Mohammadian M, Hajifathali A, et al
    Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles.
    Leuk Res. 2021;112:106751.
    PubMed     Abstract available


  50. LIESVELD JL, Baran A, Azadniv M, Misch H, et al
    A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.
    Leuk Res. 2021;112:106749.
    PubMed     Abstract available


  51. GALASSI L, Colasante C, Bettelli F, Gilioli A, et al
    Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study.
    Leuk Res. 2021;111:106747.
    PubMed    


  52. HUSELTON E, Rettig MP, Campbell K, Cashen AF, et al
    Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS.
    Leuk Res. 2021;110:106713.
    PubMed     Abstract available


  53. WONG R, Nguyen A, Wang X, Chong L, et al
    Improved resolution of phenotypic subsets in human T-ALL by incorporation of RNA-seq based developmental profiling.
    Leuk Res. 2021;110:106712.
    PubMed    


  54. AN L, Li X, Yang J
    MicroRNA-211 attenuates cell proliferation in T-cell lymphoblastic lymphoma through targeting TCF12.
    Leuk Res. 2021;110:106653.
    PubMed     Abstract available


    October 2021
  55. LUGER SM, Wang VX, Rowe JM, Litzow MR, et al
    Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.
    Leuk Res. 2021;111:106736.
    PubMed     Abstract available


  56. CHOW S, Tang K, Al-Abri M, Hall V, et al
    RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
    Leuk Res. 2021;111:106735.
    PubMed    


  57. KANNAN KK, Vellanki P, Isom S, Tawfik B, et al
    Re-induction therapy in adult patients with acute myeloid leukemia with
    Leuk Res. 2021;111:106731.
    PubMed    


  58. BAGHAEI VAJI F, Boroumand Nasr A, Rezvani A, Ayatollahi H, et al
    Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis.
    Leuk Res. 2021;111:106729.
    PubMed     Abstract available


  59. KALEKA G, Schiller G
    Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.
    Leuk Res. 2021;112:106732.
    PubMed     Abstract available


  60. PADMAKUMAR D, Chandraprabha VR, Gopinath P, Vimala Devi ART, et al
    A concise review on the molecular genetics of acute myeloid leukemia.
    Leuk Res. 2021;111:106727.
    PubMed     Abstract available


  61. PARK H, Kim I, Kim HJ, Shin DY, et al
    Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients.
    Leuk Res. 2021;111:106728.
    PubMed     Abstract available


  62. MARTINEZ-VERBO L, Estrada N, Cabezon M, Palomo L, et al
    Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
    Leuk Res. 2021;111:106726.
    PubMed    


  63. LIM K, Thompson-Peach C, Thomas D
    Neonatal heel prick mass spectrometry identifies metabolic predictors of AML latency.
    Leuk Res. 2021;109:106644.
    PubMed     Abstract available


    September 2021
  64. GOKCEN S, Bagriacik EU, Kayhan H, Yagci M, et al
    Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines.
    Leuk Res. 2021;110:106702.
    PubMed     Abstract available


  65. ESFANDBOD M, Enshaei M, Monzavi SM, Kabootari M, et al
    Radiation-Free myeloablative allogeneic hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia: A comparison of outcomes between patients with and without central nervous system involvement.
    Leuk Res. 2021;111:106703.
    PubMed     Abstract available


  66. CARRAWAY HE, Sawalha Y, Gojo I, Lee MJ, et al
    Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukem
    Leuk Res. 2021;110:106707.
    PubMed     Abstract available


  67. DU X, Liu H, Yang C, Shi X, et al
    LncRNA landscape analysis identified LncRNA LEF-AS1 as an oncogene that upregulates LEF1 and promotes survival in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106706.
    PubMed     Abstract available


  68. ALVAREZ N, Rodriguez-Garcia A, Morales ML, Gutierrez M, et al
    Clonal hematopoiesis-defining mutations have no impact on the development of thrombosis in a cohort of patients with myeloid pathology.
    Leuk Res. 2021;108:106613.
    PubMed    


  69. ALEISSA MM, Alshehri BS, Gonzalez-Bocco IH, McDonnell AM, et al
    Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib.
    Leuk Res. 2021;108:106610.
    PubMed     Abstract available


  70. LINCH DC, Hills RK, Gilkes A, Burnett AK, et al
    Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia.
    Leuk Res. 2021;108:106553.
    PubMed     Abstract available


    August 2021
  71. YU J, Du Y, Jalil A, Ahmed Z, et al
    Mutational profiling of myeloid neoplasms associated genes may aid the diagnosis of acute myeloid leukemia with myelodysplasia-related changes.
    Leuk Res. 2021;110:106701.
    PubMed     Abstract available


  72. ABRAMENKO I, Bilous N, Chumak A, Kryachok I, et al
    The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients.
    Leuk Res. 2021;110:106686.
    PubMed     Abstract available


  73. DARASKEVICIUS J, Everatt V, Vaitekenaite V, Ringeleviciute U, et al
    Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
    Leuk Res. 2021;111:106692.
    PubMed    


  74. RAHIMI Z, Ghorbani Z, Motamed H, Jalilian N, et al
    Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia.
    Leuk Res. 2021;111:106691.
    PubMed     Abstract available


  75. YOUNG PE, Kanagal-Shamanna R, Hu S, Tang G, et al
    Chronic myeloid leukemia, BCR-ABL1-positive, carrying NPM1 mutation - First case series from a single institution.
    Leuk Res. 2021;111:106685.
    PubMed    


  76. GOWIN K, Skerget S, Keats JJ, Mikhael J, et al
    Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
    Leuk Res. 2021;111:106687.
    PubMed     Abstract available


  77. GUPTA SK, Bakhshi S, Kamal VK, Gupta R, et al
    Proposal and clinical application of molecular genetic risk scoring system, "MRplus", for BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia- report from a single centre.
    Leuk Res. 2021;111:106683.
    PubMed     Abstract available


    July 2021
  78. PLESA A, Roumier C, Gutrin J, Larcher MV, et al
    Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry.
    Leuk Res. 2021;111:106673.
    PubMed    


  79. MA CE, Ghosh S, Leyshon C, Blosser N, et al
    Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
    Leuk Res. 2021;111:106674.
    PubMed     Abstract available


  80. ALSHEMMARI SH, Hamdah A, Pandita R, Kunhikrishnan A, et al
    Chronic lymphocytic leukemia in a young population.
    Leuk Res. 2021;110:106668.
    PubMed     Abstract available


  81. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
    Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
    Leuk Res. 2021;110:106666.
    PubMed     Abstract available


  82. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
    Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106665.
    PubMed     Abstract available


  83. SMITH MR, Cronin JF, Weiss RF
    Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
    Leuk Res. 2021;110:106663.
    PubMed     Abstract available


  84. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
    The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
    Leuk Res. 2021;110:106662.
    PubMed    


  85. IBRAHIM M, Chen R, Vegel A, Panse K, et al
    Treatment of myeloid sarcoma without bone marrow involvement with gemtuzumab ozogamicin-containing regimen.
    Leuk Res. 2021;106:106583.
    PubMed    


  86. GLASS JL, Derkach A, Hilden P, King A, et al
    Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.
    Leuk Res. 2021;106:106569.
    PubMed     Abstract available


    June 2021
  87. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
    Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Leuk Res. 2021;109:106650.
    PubMed    


  88. CHENG L, Zeng S, Yan D, Tu L, et al
    Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
    Leuk Res. 2021;109:106649.
    PubMed     Abstract available


  89. ZHANG Y, Feng S
    The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106647.
    PubMed     Abstract available


  90. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
    miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106643.
    PubMed     Abstract available


  91. GUPTA SK, Singh P, Chhabra R, Verma M, et al
    Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Leuk Res. 2021;109:106641.
    PubMed     Abstract available


  92. HUNTER AM, Al Ali N, Mai A, Shah S, et al
    Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
    Leuk Res. 2021;109:106640.
    PubMed    


  93. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
    Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
    Leuk Res. 2021;109:106612.
    PubMed     Abstract available


  94. SONG J, Shang B, Pei Y, Shi M, et al
    A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Leuk Res. 2021;109:106638.
    PubMed     Abstract available


  95. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
    Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leuk Res. 2021;109:106628.
    PubMed     Abstract available


  96. CHANDRA SEKARAN U, Grove CS
    Prognostic factors and their importance in relapsed and refractory AML: Comments on "Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemia" by Linch et al.
    Leuk Res. 2021;105:106572.
    PubMed    


  97. MIYAUCHI J, Kawaguchi H
    The in vitro effects of hepatoblastoma cells on the growth and differentiation of blasts in transient abnormal myelopoiesis associated with Down syndrome.
    Leuk Res. 2021;105:106570.
    PubMed     Abstract available


    May 2021
  98. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Leuk Res. 2021;108:106627.
    PubMed     Abstract available


  99. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
    Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
    Leuk Res. 2021;108:106616.
    PubMed     Abstract available


  100. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
    Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
    Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.
    PubMed    


  101. ALI H, Salhotra A, Stein AS, Nakamura R, et al
    Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
    Leuk Res. 2021;104:106579.
    PubMed    


  102. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
    Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
    Leuk Res. 2021;104:106541.
    PubMed    


    April 2021
  103. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
    Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
    Leuk Res. 2021;107:106603.
    PubMed     Abstract available


  104. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res. 2021;107:106604.
    PubMed     Abstract available


  105. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
    WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
    Leuk Res. 2021;108:106587.
    PubMed    


  106. VACHHANI P, Baron J, Freyer CW, Miller A, et al
    A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Leuk Res. 2021;107:106588.
    PubMed     Abstract available


  107. CHEN P, Redd L, Schmidt Y, Koduru P, et al
    MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
    Leuk Res. 2021;106:106584.
    PubMed     Abstract available


  108. PETRICK L, Imani P, Perttula K, Yano Y, et al
    Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
    Leuk Res. 2021;106:106585.
    PubMed     Abstract available


  109. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
    Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
    Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.
    PubMed    


  110. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
    Leuk Res. 2021;106:106567.
    PubMed    


  111. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
    Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Leuk Res. 2021;103:106540.
    PubMed     Abstract available


    March 2021
  112. PARK S, Choi EJ, Lee H, Jo DY, et al
    Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
    Leuk Res. 2021;105:106578.
    PubMed     Abstract available


  113. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
    A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Leuk Res. 2021;105:106573.
    PubMed     Abstract available


  114. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
    Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
    Leuk Res. 2021;104:106571.
    PubMed    


  115. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
    Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Leuk Res. 2021;105:106568.
    PubMed     Abstract available


  116. NI J, Hong J, Li Q, Zeng Q, et al
    Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
    Leuk Res. 2021;105:106564.
    PubMed     Abstract available


  117. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480].
    Leuk Res. 2021 Mar 26:106563. doi: 10.1016/j.leukres.2021.106563.
    PubMed    


  118. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
    Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
    Leuk Res. 2021;102:106523.
    PubMed     Abstract available


    February 2021
  119. REID JH, Perissinotti AJ, Benitez LL, Boyer D, et al
    Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
    Leuk Res. 2021;103:106539.
    PubMed     Abstract available


  120. HUANG SJ, Gerrie AS, Young S, Tucker T, et al
    Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
    Leuk Res. 2021;103:106538.
    PubMed     Abstract available


  121. SHIMIZU H, Yokohama A, Ishizaki T, Hatsumi N, et al
    Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2021;103:106535.
    PubMed     Abstract available


  122. PAROVICHNIKOVA EN, Troitskaya VV, Gavrilina OA, Sokolov AN, et al
    The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009.
    Leuk Res. 2021;104:106536.
    PubMed     Abstract available


  123. JEURKAR C, Wilde L, Leiby BE, Banks J, et al
    Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
    Leuk Res. 2021;103:106533.
    PubMed     Abstract available


  124. BOULIGNY IM, Mehta V, Isom S, Ellis LR, et al
    Efficacy of 10-day decitabine in acute myeloid leukemia.
    Leuk Res. 2021;103:106524.
    PubMed     Abstract available


  125. SOLMAN IG, Blum LK, Burger JA, Kipps TJ, et al
    Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Leuk Res. 2021;102:106520.
    PubMed     Abstract available


  126. MOORE JE, Delibert K, Baran AM, Evans AG, et al
    Targeted therapy for treatment of patients with classical hairy cell leukemia.
    Leuk Res. 2021;102:106522.
    PubMed     Abstract available


  127. SEGURO FS, Maciel FVR, Santos FM, Abdo ANR, et al
    MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
    Leuk Res. 2021;101:106516.
    PubMed     Abstract available


    January 2021
  128. MARTIN-MORO F, Nunez-Torron C, Perez-Lamas L, Jimenez-Chillon C, et al
    The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid.
    Leuk Res. 2021;101:106518.
    PubMed    


  129. OCHS MA, Perissinotti AJ, Marini BL, Burke PW, et al
    Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Leuk Res. 2021;102:106517.
    PubMed     Abstract available


  130. GHALESARDI OK, Khosravi A, Azizi E, Ahmadi SE, et al
    The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
    Leuk Res. 2021;101:106512.
    PubMed     Abstract available


  131. MONTALBAN-BRAVO G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, et al
    Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.
    Leuk Res. 2021;101:106511.
    PubMed     Abstract available


  132. ZENT CS, Ross DM
    Changing of the guard: Leukemia Research 2021.
    Leuk Res. 2021 Jan 13:106510. doi: 10.1016/j.leukres.2021.106510.
    PubMed    


  133. ACHA P, Hoyos M, Pratcorona M, Fuster-Tormo F, et al
    Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
    Leuk Res. 2021;101:106492.
    PubMed    


  134. PELCOVITS A, Pandita A, Farmakiotis D, Egan P, et al
    Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR.
    Leuk Res. 2021;100:106473.
    PubMed    


    December 2020
  135. MARCONI G, De Polo S, Martinelli G, Nanni J, et al
    Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
    Leuk Res. 2020;101:106497.
    PubMed     Abstract available


  136. ADRIANZEN-HERRERA D, Jordan-Bruno X, Devitt KA, Conant JL, et al
    Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.
    Leuk Res. 2020;100:106494.
    PubMed    


  137. YASUDA H, Morishita S, Mori Y, Tsukune Y, et al
    JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
    Leuk Res. 2020;100:106496.
    PubMed    


  138. DJAMAI H, Berrou J, Dupont M, Kaci A, et al
    Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Leuk Res. 2020;100:106490.
    PubMed     Abstract available


  139. DEMINA I, Voropayev A, Semchenkova A, Zerkalenkova E, et al
    Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2020;100:106491.
    PubMed     Abstract available


  140. YEE K, Papayannidis C, Vey N, Dickinson MJ, et al
    Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study small star, filled.
    Leuk Res. 2020;100:106489.
    PubMed     Abstract available


  141. SHAO H, Wang W, Song J, Tang G, et al
    Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Leuk Res. 2020;99:106460.
    PubMed     Abstract available


  142. KIRKIZLAR TA, Akalin H, Kirkizlar O, Ozkalemkas F, et al
    Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.
    Leuk Res. 2020;99:106463.
    PubMed     Abstract available


  143. MALLER B, Bigness A, Moino D, Greene J, et al
    Sweet's syndrome associated with hematological malignancies.
    Leuk Res. 2020;99:106461.
    PubMed     Abstract available


    November 2020
  144. BENEDETTI E, Barate C, Bruno B, Bramanti E, et al
    Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
    Leuk Res. 2020;100:106488.
    PubMed    


  145. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
    Leuk Res. 2020;100:106480.
    PubMed     Abstract available


  146. YANAGISAWA B, Perkins B, Karantanos T, Levis M, et al
    Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Leuk Res. 2020;99:106477.
    PubMed     Abstract available


  147. OBAMA K, Tabuchi T, Inoue H
    Prognostic impact of red cell distribution width in adult T-cell leukemia/lymphoma.
    Leuk Res. 2020;99:106474.
    PubMed    


    October 2020
  148. KAUFFMAN MR, Nazemidashtarjandi S, Ghazanfari D, Allen AE, et al
    Evidence that knock down of GSK-3beta in Chronic Myelogenous Leukemia cells augments IFN-gamma-induced apoptosis.
    Leuk Res. 2020;99:106464.
    PubMed     Abstract available


  149. DE BELLIS E, Ottone T, Mercante L, Falconi G, et al
    Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia.
    Leuk Res. 2020;99:106462.
    PubMed     Abstract available


    September 2020
  150. MANLEY PW, Barys L, Cowan-Jacob SW
    The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Leuk Res. 2020;98:106458.
    PubMed     Abstract available


  151. WEI L, Cong J, Yang L, Ye J, et al
    Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].
    Leuk Res. 2020 Sep 24:106446. doi: 10.1016/j.leukres.2020.106446.
    PubMed    


  152. TREMBLAY D, Feld J, Dougherty M, Czaplinska T, et al
    Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Leuk Res. 2020;98:106456.
    PubMed    


  153. MENGHRAJANI K, Zhang Y, Famulare C, Devlin SM, et al
    Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.
    Leuk Res. 2020;98:106453.
    PubMed     Abstract available


  154. CHERNG HJ, Jain N, Thakral B, Muzzafar T, et al
    Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.
    Leuk Res. 2020;98:106445.
    PubMed    


  155. BOYD K, Parcell B, Tauro S
    Immunosuppression in hematological cancer patients with Covid-19 -Uncomplicated infections but delayed viral clearance?
    Leuk Res. 2020;96:106407.
    PubMed    


  156. BROWN AL, Hiwase DK
    What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening.
    Leuk Res. 2020;96:106431.
    PubMed    


  157. NAGAHARU K, Izumi T, Ueda M, Usui E, et al
    High expression of c-Myc in chronic lymphocytic leukaemia with t(8;14)(q24.1;q32): A case report.
    Leuk Res. 2020;96:106424.
    PubMed    


    August 2020
  158. MAGANTI H, Visram A, Shorr R, Fulcher J, et al
    Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.
    Leuk Res. 2020;97:106442.
    PubMed     Abstract available


  159. CICCARELLI BT, Hu T, Wang Q, Kim JJ, et al
    Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Leuk Res. 2020;97:106440.
    PubMed     Abstract available


  160. SOLMAN IG, Blum LK, Hoh HY, Kipps TJ, et al
    Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2020;97:106432.
    PubMed     Abstract available


  161. DEEREN D
    FLAG-Ida is back in.
    Leuk Res. 2020;95:106400.
    PubMed    


  162. MOLICA S, Baumann TS, Lentini M, Levato L, et al
    The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
    Leuk Res. 2020;95:106401.
    PubMed    


    July 2020
  163. CHANAS-LARUE A, Villalpando-Rodriguez GE, Henson ES, Johnston JB, et al
    Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Leuk Res. 2020;96:106423.
    PubMed     Abstract available


  164. TRAN AA, Miljkovic M, Prasad V
    Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
    Leuk Res. 2020;96:106420.
    PubMed     Abstract available


  165. SABNIS HS, Minson KA, Monroe C, Allen K, et al
    A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Leuk Res. 2020;96:106421.
    PubMed     Abstract available


  166. D'ANGELO CR, Hall A, Woo KM, Kim K, et al
    Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    Leuk Res. 2020;96:106419.
    PubMed     Abstract available


  167. WANG Y, Luo H, Wei M, Becker M, et al
    IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia.
    Leuk Res. 2020;96:106409.
    PubMed     Abstract available


  168. CASELLAS ROMAN HL, Venugopal K, Feng Y, Shabashvili DE, et al
    DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
    Leuk Res. 2020;94:106372.
    PubMed    


  169. GEORGE G, Rezazadeh A, Zook F, Pearl N, et al
    Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
    Leuk Res. 2020;94:106368.
    PubMed    


    June 2020
  170. KALLEN ME, Koka R, Singh Z, Sanchez-Petitto G, et al
    Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
    Leuk Res. 2020;96:106406.
    PubMed    


  171. BRITT A, Mohyuddin GR, McClune B, Singh A, et al
    Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Leuk Res. 2020;95:106402.
    PubMed     Abstract available


  172. ZHENG FY, Lu AD, Zuo YX, Jia YP, et al
    Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
    Leuk Res. 2020;95:106405.
    PubMed     Abstract available


  173. GOLDBERG AD, Atallah E, Rizzieri D, Walter RB, et al
    Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
    Leuk Res. 2020;95:106385.
    PubMed     Abstract available


    May 2020
  174. O'CONNOR-BYRNE N, Quinn J, Glavey SV, Lavin M, et al
    Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy.
    Leuk Res. 2020;95:106390.
    PubMed    


  175. SOTO-MERCADO V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, et al
    Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism.
    Leuk Res. 2020;95:106389.
    PubMed     Abstract available


  176. AGUILERA-DIAZ A, Larrayoz MJ, Palomino-Echeverria S, Vazquez I, et al
    Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.
    Leuk Res. 2020;95:106386.
    PubMed     Abstract available


  177. SAITO T, Itoh M, Tohda S
    Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
    Leuk Res. 2020;94:106383.
    PubMed     Abstract available


  178. WANG X, Resendes NM, Shanahan L, Hutchinson L, et al
    Chronic neutrophilic leukemia, a rare case of leukocytosis.
    Leuk Res. 2020;94:106384.
    PubMed    


  179. NAVADA SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, et al
    Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Leuk Res. 2020;94:106369.
    PubMed     Abstract available


  180. NAYMAGON L, Mascarenhas J
    Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
    Leuk Res. 2020;94:106356.
    PubMed     Abstract available


  181. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    Corrigendum to "STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype" [Leuk. Res. 78 (2019) 21-23].
    Leuk Res. 2020 May 4:106148. doi: 10.1016/j.leukres.2019.
    PubMed    


  182. TALATI C, Goldberg AD, Przespolewski A, Chan O, et al
    Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
    Leuk Res. 2020;93:106367.
    PubMed     Abstract available


    April 2020
  183. PANEESHA S, Pratt G, Parry H, Moss P, et al
    Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.
    Leuk Res. 2020;93:106366.
    PubMed    


  184. FRANCH-SARTO M, Anglada Escalona JR, Tuset Beltran V, Ribera Santasusana JM, et al
    A unique case of relapse of plasma cell leukemia in the vitreous humor.
    Leuk Res. 2020;93:106357.
    PubMed    


  185. OLIVA EN, Tripepi GL
    Letter to the Editor on the original article "A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia" by Bryant Al, et al. 2018.
    Leuk Res. 2020;93:106355.
    PubMed    


  186. DRUHAN LJ, Lance A, Hamilton A, Steuerwald NM, et al
    Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia.
    Leuk Res. 2020;92:106349.
    PubMed    


  187. BRUNNER AM
    The highs and lows of venetoclax with hypomethylating agents for refractory AML.
    Leuk Res. 2020;91:106320.
    PubMed    


    March 2020
  188. GAVILLET M, Carr Klappert J, Spertini O, Blum S, et al
    Acute leukemia in the time of COVID-19.
    Leuk Res. 2020;92:106353.
    PubMed    


  189. YANG W, Xie J, Hou R, Chen X, et al
    Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression.
    Leuk Res. 2020;92:106351.
    PubMed     Abstract available


  190. SODERLUND S, Persson I, Ilander M, Guilhot J, et al
    Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
    Leuk Res. 2020;90:106310.
    PubMed     Abstract available


    November 2019
  191. MASSE A, Roulin L, Pasanisi J, Penneroux J, et al
    BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
    Leuk Res. 2019;87:106269.
    PubMed     Abstract available


    June 2019
  192. KINSELLA FAM, Inman CF, Gudger A, Chan YT, et al
    Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
    Leuk Res. 2019;83:106173.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: